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The human epithelial mucin MUC1 is a high molecular glycoprotein
characterized by heavy glycosylation, and is known to be expressed
on various human cancers including mammary, pancreatic gastric
and colon cancers (Burchell et al, 1987; Lan et al, 1990; Ogata et al,
1992; Ho et al, 1995; Hakomori, 1996; Taylor-Papadimitriou and
Finn, 1997). What distinguishes MUC1 from other tumour-associ-
ated antigens is that MUC1 mucin was demonstrated to be strongly
recognized by CTLs in a MHC- unrestricted manner (Barnd et al,
1989). The mechanism of the MUC1 recognition by T-lymphocytes
has extensively been studied (Barnd et al, 1989; Agrawal et al, 1996;
Pecher and Finn, 1996; Magarian-Blander et al, 1998). 
Approximately 20 to 100 tandem repeats of the conserved 20
amino acid sequences in the MUC1 core protein are thought to
assure adequate affinity with antigen-binding regions of TCR
(Swallow et al, 1987; Gendler et al, 1988, 1990; Siddiqui et al,
1988), and this is proposed to activate cytotoxic T-lymphocytes
(CTLs), even if the antigenic peptide is not presented in the
context of MHC molecules. The exposure of the epitopes in the
tandem repeat domain was also known to be significantly affected
by carbohydrate structures bound on the core protein (Bara et al,
1993). Normal epithelial cells express MUC1, but its glycosyla-
tion on normal epithelial cells was reported to be different from
that on cancer cells (Hanisch et al, 1989; Lloyd et al, 1996). Long
and complexly branched carbohydrates on normal epithelial cells
ordinarily mask MUC1 core proteins at the cell surface, while
MUC1 in cancer cells express much shorter carbohydrate chains,
such as sialylated or non-sialylated Tn- and TF-antigens, and this
aberrant glycosylation of MUC1 is proposed to be important in
inducing significant CTL response in patients with cancer. Even
more direct involvement of certain carbohydrate determinants in
T-cell recognition is suggested (Böhm et al, 1997). 
MUC1 is assumed to be a good candidate for adoptive
immunotherapy against human cancers (Akagi et al, 1997; Karanikas
et al, 1997; Samuel et al, 1998; Acres et al, 2000; Carmon et al, 2000;
Wright et al, 2000; Kontani et al, 2000). However, the reaction of
autologous CTLs against MUC1 mucin expressed on autologous
tumour cells in patients has not been thoroughly characterized. For
the development of effective immunotherapy against cancer, it would
be important to use the autologous experimental system. In this
study, we investigated the possible relationship between expression
of MUC1 mucin on cancer cells and the lytic activity of autologous
CTLs, and attempted to clarify the mechanism by which autologous
cancer cells escape from the lytic activity of autologous lymphocytes. 
MATERIALS AND METHODS 
Cell lines, monoclonal antibodies and other reagents 
Cultured human cell lines, ZR-75-1, BT-20, and T-47D were
obtained from American Type Culture Collection (Rockville,
MD). Monoclonal antibodies, DF3, 115D8, B72.3 and CC49 were
provided from Toray-Fuji Bionics Inc. (Tokyo, Japan). SM3 was
purchased from Cymbus Bioscience Ltd. (Southampton, UK), and
TKH6 was from Otsuka Pharmaceutical Co (Tokushima, Japan).
The speficities of these antibodies are summarized in Table 1.
SNH3, which is reactive to sialyl-LeX (Takada et al, 1993), was a
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kind gift from Dr Sen-itiroh Hakomori, Biomembrane Institute,
Seattle, WA. Anti-human CD4 and CD8 monoclonal antibodies
were purchased from Seikagaku Corp (Tokyo, Japan), and anti-
human TCRab monoclonal antibody was from Cosmo Bio
Co, Ltd (Tokyo, Japan). Dispase was purchased from Godo
Shusei Co Ltd (Tokyo, Japan), Ficoll-Conray Lymphosepal from
Immuno-Biological Laboratories (Gunma, Japan) and Na2
51CrO4
from DuPont-NEN (Boston, MA). Sialidase and Geneticin (G418)
were from GIBCO BRL (Tokyo, Japan). 
Flow cytometric analysis 
Breast cancer cell lines were suspended in PBS and incubated with
anti-MUC1 monoclonal antibodies diluted on ice for 30 min. After
3 washes in cold PBS, the cells were incubated with fluorescein
isothiocyanate-conjugated anti-mouse Ig diluted at 1/1000 on ice
for 30 min. Flow cytometric analyses were performed using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA)
following 3 washes in cold PBS. 
Tumours from patients with breast cancer and
immunohistochemical study 
26 female patients ranging in age from 32 to 77 and in clinical
stage from 1 to 3 were studied. Clinical features of the patients are
summarized in Table 2. A part of tumour specimens obtained from
the main breast tumours from these patients was either fixed in
10% formalin and embedded in paraffin or frozen in OCT
compound in liquid nitrogen. Paraffin-embedded sections were
incubated with monoclonal antibodies diluted to appropriate
concentrations in PBS at room temperature for 2 h following pre-
incubation in 0.2% hydrogen peroxide-containing methanol to
block non-specific binding sites. After 3 washes in PBS, the
sections were incubated with peroxidase-conjugated anti-mouse
IgG diluted at 1/200 in PBS at room temperature for 30 min. They
were washed in PBS 3 times and incubated in 5 mM Tris-HCl
containing diaminobenzidine to visualize for 10 min. After
washing in distilled water, nuclear compartments of cancer cells
were stained in haematoxylin solution. After dehydration in 100%
ethanol, the sections were mounted in 50% glycerin. Frozen
sections were fixed in 50% chloroform solution and stained
according to the indirect peroxidase-staining technique described
above. The percentage of positive cells was calculated by the
number of cancer cells positively stained out of 500 cancer cells
counted in each specimen. 
Preparation of breast cancer cells from patients with
breast cancer 
Breast cancer cells were freshly isolated from main breast
tumours of the above patients at the time of surgical operations.
The study was performed with approval by the institutional
review board. Resected tumour samples were minced and incu-
bated in RPMI 1640 supplemented with Dispase at the concen-
tration of 10 000 PU ml–1 at 37˚C for 60 min to obtain single cell
suspensions. The suspensions were layered on the top of step
gradients, from the bottom comprising 100% and 75%
Lymphosepal and centrifuged at 400 ´ g for 30 min. Tumour
cells were collected from the interface of the sample and 75%
Lymphosepal layer and resuspended in RPMI 1640 containing
2% FCS. A MUC1-deficient cell line, NZK-K1, was established
from a main tumour of a 45-year-old female breast cancer
patient, by grafting the tumour specimens subcutaneously in
female SCID mice, which were purchased from Charles River
Inc (Hino, Japan). NZK-K1 cells completely lacked expression
of MUC1 mucin at the cell surface as well as expression of
MUC1 mRNA as ascertained by Northern blotting. 
Table 1 Specificity of antibodies used for detection of antigenic
determinants carried by MUC-1 mucin 
Antibodies Antigenic structures detected 
Anti-MUC-1
DF3 TRPAPGS 
SM3 PDTRP 
115D8 Glycopeptidea
Anti-carbohydrate
TKH6 GalNAca-O-Ser/Thr 
B72.3 NeuAca 2® 6GalNAca1-O-Ser/Thr(Sialyl Tn) 
CC49 NeuAca2 ® 6(Galb1®3) GalNAca 1-O-Ser/Thr 
SNH3b NeuAca2 ®3Galb1®4 (Fuca1 ®3)GlcNAc b1®R 
GalNAc, N-acetyl-galactosamine; NeuAc, N-acetyl-neuraminic acid; Gal,
galactose; Fuc, fucose; GlcNAc, N-acetyl-glucosamine. a115D8 is reactive to
fully glycosylated MUC1 as well as underglycosylated tumour-associated
MUC1. However, it failed to react to any of the MUC1 peptides of various
length so far tested in the Tumor Differentiation-4 workshop (Blockzjil et al,
1998; Price et al, 1998). The antibody also failed to react to any hitherto-
known carbohydrate determinants, while a periodate-treatment inhibited the
binding (Dai et al, 1998). bSNH3 was used as a control anti-carbohydrate
antibody since the determinant defined by this antibody (sialyl Lex) is known
to be carried frequently by MUC-1 mucin, but is not thought to be intimately
involved in cancer cell lysis by CTLs. 
Table 2 Clinical features of breast cancer patients studied 
Patient no. Age Clinical stage Histological type 
1 45 t2n1m0 SCa
2 61 t2n0m0 PTb
3 39 t1n0m0 PT 
4 64 t2n0m0 SC 
5 50 t2n0m0 SC 
6 77 t2n0m0 SC 
7 68 t3n0m0 SC 
8 61 t3n0m0 SC 
9 67 t3n1m0 Med.c
10 47 t2n0m0 PT 
11 59 t2n1m0 Med. 
12 53 t2n0m0 STd
13 42 t4n0m0 SC 
14 54 t2n0m0 ST 
15 45 t2n0m0 SC 
16 45 t2n0m0 SC 
17 71 t2n0m0 PT 
18 35 t2n0m0 SC 
19 60 t2n1m0 SC 
20 67 t3n0m0 SC 
21 46 t2n0m0 SC 
22 44 t1n0m0 Med. 
23 38 t3n2m0 Med. 
24 47 t2n0m0 PT 
25 32 t2n0m0 ST 
26 56 t2n0m0 Comedo 
a Scirrhous type; b Papillo-tubular type; c Medullary type; d Solid tubular type. 1260 K Kontani et al 
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Preparation of peripheral blood mononuclear cells
(PBMC) and cytotoxicity assay 
Heparinized peripheral blood samples obtained from the patients
were diluted in the same volume of PBS, layered on Lymphosepal
and centrifuged at 400 ´ g at room temperature for 30 min.
PBMCs were collected from the interface of the sample and the
Lymphosepal layer, then resuspended in RPMI 1640 containing
2% FCS. 
Breast cancer cell lines or cancer cells obtained from cancer
patients were incubated with Na2
51CrO4 at 37˚C for 60 min. Radio-
labelled 104 cells were transferred to a 96-well U-bottom culture
plate containing 5 ´ 105 PBMCs prepared in 200 ml RPMI 1640
supplemented with 10% FCS and 5 ´ 10–5 M 2-mercaptoethanol
following 3 washes in culture medium. They were incubated at
37˚C for 18 hours to measure the cytotoxicity as previously
reported (Finke et al, 1990; Smyth and Ortaldo, 1993; Kontani 
et al, 2000). For inhibiting the recognition of antigenic structures
by effector cells, target cells were pre-incubated with anti-MUC1
monoclonal antibodies at 37˚C for 45 min prior to co-culture with
effector cells. For characterization of effector cell population
responsible for the tumour cell lysis, PBMCs were treated with
anti-TCRab, -CD4 or -CD8 antibodies at 37˚C for 45 min
followed by co-incubation with radio-labelled target cells. After
incubation of target cells and PBMCs for 18 h, the supernatant was
collected from each well and counted for the release of 51Cr from
the lysed target cells, using LKB-Wallac Minigamma 1275
(Wallac Oy, Finland). The percentage of chromium release was
determined by the formula: % Lysis = 100 ´ (Experimental release–
Spontaneous release)/ (Maximal release–Spontaneous release). 
Transfection of a breast cancer cell line with MUC1
cDNA 
MUC1 cDNA expression vector, pCMV5-PEM (Gendler et al,
1990), was a kind gift from Dr Sandra J Gendler (Mayo Clinic
Scottsdale, Scottsdale, Arizona). Transfection of a MUC1-deficient
cell line, NZK-K1, with the cDNA was performed using the electro-
poration technique as described (Potter et al, 1984). Briefly, NZK-
K1 cells, 400 ml of 5 ´ 106 cells ml–1 in Dulbecco’s PBS buffer, were
transfected with 1 mg of pDKOF.muc1 using a ECM600® Electro-
Cell Manipulator (BTX Inc, San Diego, USA) as follows: 400 ml of
5 ´ 106 cells ml–1 in Dulbecco’s PBS buffer were pulsed at 150 V, 72
ohms, 500 mGarads in a sterile electroporation cell. Aliquots of the
electroporated cells were added to normal medium and grown for 2
days. G418 was added at 600 mg ml–1 to select stable transfectants.
Resistant clones appeared within 4–5 weeks, and colonies of inde-
pendent transfectants were obtained by limiting dilution and
screened for expression of the MUC1 epitopes. 
RESULTS 
Cytotoxic activity of PBMCs from patients with breast
cancer against autologous cancer cells and its
correlation to MUC1 expression on cancer tissues 
When freshly isolated PBMCs from the patients were co- incu-
bated with autologous cancer cells, 8 (31%) out of 26 cases
showed statistically significant positive cytotoxic activity for
autologous cancer cells (Figure 1). As many as 18 patients,
however, displayed only negligible killing activity. This did not
seem to be due to the malfunction of lymphocytes prepared from
the patients, since significant cytolytic activity was observed when
well-known cultured breast cancer cell lines were used as target
cells instead of autologous cancer cells in some assays. During the
course of this study, we noticed that the degree of killing correlated
well with the expression of MUC1-related determinants on autolo-
gous cancer cells. 
Accordingly, the patients were divided into 2 groups of cytotox-
icity-positive (n = 8) and -negative (n = 18) cases, respectively.
The immunohistochemical expression of MUC1-tandem repeat
epitopes and related carbohydrate determinants was carefully
examined and compared between the 2 groups. The results indi-
cated that the expression of MUC1 tandem repeat epitope defined
by the DF3 antibody and that of glycopeptide epitope defined by
the 115D8 antibody were significantly higher in the cytotoxicity-
positive cases than in the cytotoxicity-negative cases (Figure 2).
Among MUC1-related carbohydrate determinants, expression of
the CC49-defined determinant turned out to be significantly higher
in the cytotoxicity-positive cases compared to that in the cytotoxi-
city-negative cases (Figure 2). It was noted that the calculated
statistical significance was as high as P = 0.0005 for the DF3 anti-
body, 0.0045 for CC49, followed by 0.0083 for 115D8. 
All of the 8 patients with positive cytotoxicity showed strong
MUC1-core epitope expression as well as CC49-defined carbohy-
drate determinants in their tumours. On the other hand, among the
18 cytotoxicity-negative cases, 14 showed markedly reduced or no
expression of the MUC1 epitopes and/or CC49-related carbohy-
drate determinants. These results suggested that the major cause of
unresponsiveness of CTLs in cytotoxicity-negative cases to autol-
ogous tumour cells was due to the loss or decreased expression of
MUC1-related epitopes, rather than any functional disturbance of
lymphocytes. There were only 4 cases in which tumour cells
expressed MUC1 epitopes and CC49-defined determinants at a
level comparable to those in cytotoxicity- positive cases, neverthe-
less being unresponsive to autologous CTLs. 
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Figure 1 Cytotoxic activity of PBMCs from patients with breast cancer
against autologous cancer cells. Breast cancer cells, prepared as described
in ‘Material and Methods’, were 51Cr-labelled and incubated with freshly
isolated PBMCs for 18 h. The percentage of tumour cell lysis was plotted 
for each patient. Lytic activity more than 6.3% was statistically significant 
(P < 0.05) Isolation of cytotoxicity-resistant breast cancer cell line
from non-responder patients 
We next established a breast cancer cell line, NZK-K1, from
cancer tissues of one of the patients showing negligible autologous
cytotoxic activity. This cell line completely lacked the expression
of MUC1 epitopes defined by all 6 monoclonal antibodies in flow
cytometric analysis (Figure 3, upper panel). The cells also lacked
the MUC1 mRNA expression ascertained by Northern blotting,
while expressing a high level of class I MHC molecules. The
NZK-K1 cells were not lysed by PBMCs prepared from autolo-
gous peripheral blood or from healthy donors, while the control
cultured breast cancer cell lines such as ZR-75–1, BT-20 and T-
47D were significantly killed by the same PBMCs as shown in
Figure 4A. 
The killing of the ZR-75–1, BT-20 and T-47D cells by PBMCs
was inhibited in varying degrees by the DF3, 115D8 or SM3 anti-
bodies directed to the MUC1 epitopes (Figure 4B). These 3 cell
lines significantly expressed the epitopes defined by SM3 as well
as DF3 or 115D8 on flow cytometric analyses (data not shown).
The killing was also inhibited by the addition of the CC49 and to a
lesser extent by the B72.3 antibodies, which define the MUC1-
related carbohydrate determinants (Figure 4B). The killing of
these control cell lines by PBMCs was virtually not inhibited by
antibodies against class I or II MHC antigens (Figure 4B). Anti-
TCRab as well as CD4 antibodies were shown to inhibit the lysis
of target cells by PBMCs, while anti-CD8 antibody did not affect
the cytotoxicity (Figure 4C). This suggested that the CTLs partici-
pating in the killing of these cells are MHC-non-restricted, and are
CD4+ TCRab+ lymphocytes as characterized earlier (Barnd et al,
1989; Jerome et al, 1993). 
Induction of cytotoxic activity against MUC1 cDNA-
transfected autologous breast cancer cell line 
We transfected MUC1 cDNA to the NZK-K1 cells, and obtained a
subclone, termed NZK-muc. The NZK-muc cells moderately
expressed the MUC1 epitopes defined by the DF3 and 115D8 anti-
bodies (Figure 3, middle panel). The SM3-defined epitope
and MUC1-related carbohydrate determinants were, however,
only weakly expressed on the NZK-muc cells (Figure 3, middle
panel). Sialidase treatment of the transfectant cells enhanced
the expression levels of the SM3 tandem repeat epitope and of
Modulation of MUC1 mucin on breast cancer 1261
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Figure 2 Relationship between MUC1 expression in cancer cells and its
ability to elicit anti-tumour immunity. The patients studied were divided into 2
groups, cytotoxicity-positive (n = 8) and -negative (n = 18) cases, according
to the result of the autologous cytotoxicity assay. Mean percentages of
cancer cells positive for the reactivity to each anti-MUC1 antibody were
compared between the 2 groups. Statistical analyses were performed by
Student’s t-test 
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Figure 3 Phenotypic analysis of MUC1 transfectants by flow cytometry. The MUC1 deficient parent cell line, NZK-K1, a MUC1 transfectant, NZK-muc, and
sialidase-treated NZK-muc were stained with anti-MUC1 antibodies. MUC1 expression of these cell lines was studied as described in ‘Materials and Methods’ mucin-associated carbohydrate determinants, suggesting some
sialylated carbohydrate side chains had masked expression of the
mucin associated epitopes on untreated NZK-muc transfectant
cells (Figure 3, lower panel). 
When NZK-K1 or NZK-muc cells were used as target cells in
cytotoxic assays with autologous PBMCs prepared from the
same patient, the parent NZK-K1 cells were scarcely killed by
the PBMCs, while significant killing activity was observed
with NZK-muc transfectant (Figure 5). When sialidase-treated
NZK-muc cells were used as target cells, the autologous PBMCs
exhibited strong lytic activity comparable to that obtained with
the high MUC1 expressor T-47D, which served as a positive
control in these assays (Figure 5). This indicated that autologous
CTLs in the peripheral blood contained significant killing
activity against tumour cells, and that the unresponsiveness of
autologous CTLs initially observed with this patient was due to
the loss of MUC1 antigenic epitopes from the surface of autolo-
gous cancer cells. 
DISCUSSION 
In this study we investigated cytotoxicity of autologous lympho-
cytes against autologous tumour cells in patients with breast
cancer. We confirmed an earlier notion (Barnd et al, 1989;
Magarian-Blander et al, 1996, 1998) that certain T-lymphocyte
populations that recognize the MUC1 mucin occur in peripheral
blood of patients with breast cancers, as well as normal individ-
uals, without any priming in vitro. Effector cells involved in the
MUC1-mediated killing reaction were mainly TCRab+CD4+
T-lymphocytes, and the recognition of the MUC1 mucin was
largely MHC-independent. It would seem unlikely that T-lympho-
cytes in freshly isolated PBMCs from normal donors could recog-
nize the tumour antigen without any prior in vitro priming.
However, naive T-lymphocytes may have a chance to encounter
mucin shed from inflamed glandular epithelial cells, or processed
and presented by phagocytes following apoptotic death of the
epithelial cells even in normal individuals. Levels of serum soluble
MUC1 mucin are known to be elevated in patients with cancer,
and even the basal levels of the mucin are detected in the sera of
normal individuals as well (Burchell et al, 1984; Devine et al,
1993; Willsher et al, 1993). The presence of MUC1-reactive T-
lymphocytes is reported to occur in multiparous women (Agrawal
et al, 1996), and even humoral antibodies directed to MUC1 mucin
appear in the sera of cancer patients (Kotera et al, 1994; von
Mensdorff-Pouilly et al, 2000). These findings suggest that some
populations of T-lymphocytes have already been primed with
MUC1 mucin and can be re-activated immediately in response to
cancer cells expressing the mucin. It is possible that cancer
patients as well as some normal individuals may have already in
vivo-primed T-lymphocytes specific for MUC1 mucin in their
PBMCs (Jerome et al, 1995, 1997). 
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Figure 4 Cytotoxic activity of PBMCs against cultured breast cancer cell
lines. In panel A, 51Cr-labelled 1 ´ 104 breast cancer cells were incubated
with 5 ´ 105 PBMCs obtained from normal donors in each well for 18 h as
indicated in ‘Materials and Methods’. NZK-K1 is the cell line established from
non-responder. Cultured breast cancer cell lines ZR-75-1, BT-20 and T-47D
serve as positive control. The effector/target ratio was 50:1. Panel B,
inhibitory effect of anti-MUC1 monoclonal antibodies on the cytotoxicity
against breast cancer cell lines. ZR-75-1, BT-20 and T-47D, were pretreated
with anti-MUC1 antibodies or anti-MHC antibodies at 37˚C for 45 min prior to
co-incubation with PBMCs. In C PBMCs were pretreated with anti-TCR ab ,
-CD4 or -CD8 antibodies at 37˚C for 45 min prior to co-cultivation with radio-
labelled target cells, ZR-75-1 
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Figure 5 Cytotoxic activity of autologous PBMCs against MUC1
transfectants. 51Cr-labelled NZK-K1, NZK-muc, and sialidase-treated NZK-
muc cells were incubated with autologous PBMCs at effector/target ratio of
50:1 for 18 hours. The cultured breast cancer cell line T-47D served as a
positive control for the cytotoxic activity. The amounts of isotope released
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A significant correlation was observed between the expression of
the MUC1 epitopes in cancer tissues and the killing activity of auto-
logous lymphocytes against the cancer cells in patients with breast
cancer. These antibodies directed to MUC1 tandem repeats were
effective in inhibiting the lysis of the target cells in cytotoxicity
assay employing well-known breast cancer cell lines. Some anti-
bodies directed to the mucin-associated aberrant carbohydrate deter-
minants, such as CC49, also exerted a comparable inhibitory effect
on the lysis of tumour cells. Expression of CC49-defined carbohy-
drate determinants in autologous cancer cells was also found to
significantly correlate with killing activity of CTLs in patients with
breast cancer. Normal glycosylation of MUC1 is known to inhibit
the recognition of the molecule by CTLs, and effective induction of
lytic activity is proposed to be achieved when the MUC1 molecule
is aberrantly glycosylated and the antigenic epitopes are exposed on
the surface (Kotera et al, 1994; Jerome et al, 1997). In line with this,
all of the cancer patients with significant lytic activity in the autolo-
gous cytotoxicity assays demonstrated a strong expression of
MUC1 epitopes as well as MUC1-related aberrant carbohydrate
determinants on the cancer cells. These results collectively indicate
that the susceptibility of the cancer cells to MUC1-specific CTLs is
highly dependent on the appropriate expression of the antigenic
epitopes on cancer cells. 
T-cell tolerance towards tumour cells is recently suggested to be a
major hindrance to the development of effective immune responses
against tumours from experiments using human MUC1 transgenic
mice (Gong et al, 1998; Rowse et al, 1998). However, the unrespon-
siveness of PBMCs to the autologous cancer cells observed in this
study does not seem to be caused by dysfunction of the effector cells
in most patients. Expression of MUC1 epitopes as well as CC49-
defined carbohydrate determinants on cancer cells was significantly
reduced in patients who did not show the killing of autologous
tumour cells. In these patients, the unresponsiveness of CTLs could
be ascribed to the reduced MUC1 epitope expression on the autolo-
gous tumour cells. The PBMCs prepared from a cancer patient,
which had exhibited no killing activity in initial autologous tumour
cell lysis, were shown to exert significant cytotoxic activity after the
expression of MUC1 mucin was recovered on the autologous cancer
cells by transfecting MUC1 cDNA. This again confirmed that
immune tolerance was not the major hindrance to the development
of an effective cytotoxic reaction against the autologous tumour
cells, and indicated that the loss of the MUC1 expression and/or anti-
genic modulation was the major mechanism by which autologous
tumour cells escape from host immune effector cells. 
MUC1 mucin is thought to be an important candidate for the
target molecule in immunotherapy against cancer. Several cancer
vaccines have been proposed for induction or augmentation of
anti-tumour immunity, including MUC1 molecules covalently
linked to the yeast cell-wall polysaccharide, synthetic peptide
encapsulated with monophosphoric lipid A adjuvant, or recombi-
nant vaccinia viruses expressing a modified MUC1 gene (Akagi
et al, 1997; Karanikas et al, 1997; Samuel et al, 1998). The escape
mechanism of the cancer cells due to the modulation of MUC1
antigenicity observed in this study, however, should be taken in-
to consideration, when targeting the MUC1 mucin for
immunotherapy of cancer. 
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